RE:RE:Damn 20%
No insider buying, one thing that has been frustrating for me since it would add credibility to their whole vision and project. Its been the most undervalued play in this sector by a country mile, mainly because the market has attached a very inflated value on pharma grade patent biz models. I dont think this will last long. Yes. Sap prob getting approved by end of summer and more m & a news lined up very likely.